What We're Reading: Page 162
Industry reads hand-picked by our editors
Feb 09, 2021
-
The New York Times
A Few Covid Vaccine Recipients Developed a Rare Blood Disorder
-
STAT
Woodcock vs. Sharfstein: A head-to-head comparison of Biden’s top choices for FDA commissioner
-
The Financial Times
Hong Kong biotech sector booms on buoyant markets and pandemic
-
The Wall Street Journal
What to Do When There’s a Covid-19 Vaccine Glut
Feb 08, 2021
-
STAT
How a journal's censure inflamed debate over Biogen's Alzheimer's drug
-
Vogue
Science Not Politics: How Dr. Rochelle Walensky is Saving the CDC
-
Financial Times
How AstraZeneca’s vaccine was hit by flawed trials, defects and politics — but might still save the world
-
Endpoints News
‘Can’t say no’: Kite Therapeutics taps Frank Neumann as new head of clinical development
Feb 05, 2021
-
POLITICO
Biden health team hatches new vaccine strategy as variant threat builds
-
The Wall Street Journal
Merck CFO Brings Corporate Strategy Experience to CEO Role
-
FiercePharma
Roche hit by worst-case biosim assault — to the tune of $5.6B — as COVID-19 hurts Ocrevus
-
BioSpace
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
Feb 04, 2021
-
Reuters
Merck anti-baldness drug Propecia has long trail of suicide reports, records show
-
The New York Times
McKinsey Settles for $573 Million Over Role in Opioid Crisis
-
FiercePharma
Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital
-
STAT
23andMe to go public via Richard Branson's SPAC
Feb 03, 2021
-
The New York Times
Study Finds AstraZeneca Shots Drastically Cut Transmission
-
FierceBioTech
Novo Nordisk's long-term chief scientific officer Thomsen retires, becomes its Foundation chief
-
In the Pipeline
Myths of Vaccine Manufacturing
-
Evaluate Vantage
Reality Bites for Amgen's bispecifics
Previous
